Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-403-6707380
Debt
Current Ratio5.46
Quick Ratio5.02
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash Flow2.87
Price / Book5.36
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Oncolytics Biotech (TSE:ONC) Frequently Asked Questions
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."
How were Oncolytics Biotech's earnings last quarter?
Oncolytics Biotech, Inc. (TSE:ONC) released its earnings results on Monday, November, 12th. The company reported ($0.20) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.09. View Oncolytics Biotech's Earnings History.
When is Oncolytics Biotech's next earnings date?
What price target have analysts set for ONC?
2 brokers have issued twelve-month target prices for Oncolytics Biotech's stock. Their forecasts range from C$3.25 to C$11.00. On average, they expect Oncolytics Biotech's share price to reach C$7.13 in the next year. This suggests a possible upside of 148.3% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.
What is the consensus analysts' recommendation for Oncolytics Biotech?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.
Has Oncolytics Biotech been receiving favorable news coverage?
News stories about ONC stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oncolytics Biotech earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Dr. Matthew C. Coffey, Pres, CEO & Director
- Mr. Kirk J. Look, Chief Financial Officer
- Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
- Mr. Michael Moore, VP of Investor Relations & Corp. Communications
- Dr. Rita Laeufle, Chief Medical Officer
How do I buy shares of Oncolytics Biotech?
Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of ONC stock can currently be purchased for approximately C$2.87.
What is Oncolytics Biotech's official website?
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.
MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
